
|Articles|May 1, 2004
Microplasmin receives orphan drug protection
Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
2
Meta's AI glasses for veterans: Canto-Sims, OD on closing the access gap
3
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
4
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
5


























